Charles Moore,  —

Charles Moore has a long-proven track record in both print and digital journalism, touching on a wide range of subjects, from biotech and healthcare to politics and technology. He contributes substantial feature articles about PH research and development for the news site.

Articles by Charles Moore

US Patent Dispute Simmers Over Treprostinil-based Therapies for PAH

U.S. specialty biopharmas SteadyMed and United Therapeutics both issued media releases recently commenting on a ruling by the U.S. Patent and Trademark Office (USPTO) that declared invalid a United Therapeutics patent related to the drug treprostinil, a synthetic analogue of prostacyclin. Prostacyclin and its analogues are widely used in…

Mifcare Receives Support from HTaPFrance, Inserm to Develop New PAH Therapies

Paris-based biotechnology company Mifcare is getting support from the French pulmonary hypertension patients’ association HTaPFrance for the development of new anti-inflammatory therapies for pulmonary arterial hypertension (PAH). Melanie Gallant-Dewavrin, director of HTaPFrance, said promoting research to fight PAH is one of her association’s goals, “which is why I do not hesitate to…

SteadyMed Hires Pulmonary Hypertension Advocacy Veteran

SteadyMed Therapeutics, a California-based specialty pharmaceutical company that develops drug products for treating orphan and high-value diseases with unmet non-oral delivery needs, has hired Carl Hicks, Jr. to take on the newly created role of Vice President of PH Patient Advocacy and Community Relations. Hicks is a 20-year…

BePHenomenal.com Aims to Educate and Engage People with PH

November is Pulmonary Hypertension Awareness Month and, in recognition, SteadyMed has announced the launch of its new website, BePHenomenal.com, dedicated to educating people with pulmonary hypertension (PH) so as to empower them to live the healthiest and most PHenomenal lives possible. The Pulmonary Hypertension Association notes…

Pulmonary Hypertension: One Family’s Long, Hard Journey

Erica Huntzinger, today a pulmonary hypertension (PH) activist and advocate, remembers her mother, Susan, beginning to experience PH symptoms in her mid-30s, but going improperly undiagnosed for more than a quarter century. During this period, Susan suffered two respiratory failures, a heart attack, and as many as five emergency room visits a year…

Step Up for PHAwareness on World Pulmonary Hypertension Day May 5

On May 5, more than 80 organizations around the world will participate in activities designed to raise awareness of this often-misdiagnosed disease and to celebrate the lives of people living with what is called pulmonary hypertension (PH), or pulmonary arterial hypertension (PAH) — a condition of high blood pressure in…

Novel PAH Cell Therapy Shows Safety in Early Phase 1 Results

Haifa, Israel-based Pluristem Therapeutics Inc. announced that it has received a notice from United Therapeutics Corporation ending its licensing agreement for development of the cell-based candidate PLX-PAD for the treatment of pulmonary arterial hypertension (PAH). Under the agreement’s terms, Pluristem will recover full rights to PLX-PAD and retain all…

Ontario PAH Patients Rally to Demand Public Funding of Drug Opsumit

Residents of the Canadian province of Ontario affected by pulmonary arterial hypertension (PAH) gathered at the Queen’s Park provincial legislature in Toronto this week in hope of convincing Ontario’s Health Minister Dr. Eric Hoskins to make the drug Opsumit (macitentan) publicly accessible as a treatment option for Ontario…